Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
This article was originally published in Scrip
Executive Summary
Pfizer Inc. released positive Phase III data from two induction trials testing its oral Janus kinase inhibitor Xeljanz (tofacitinib) in patients with the inflammatory bowel disease ulcerative colitis, but the company will await the results of another Phase III maintenance study before filing for an indication expansion.
You may also be interested in...
FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach
Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.